Advances in the gene-editing technology known as CRISPR-Cas9 over the past 15 years have yielded important new insights into the roles that specific genes play in many diseases. But to date this ...
Sickle-cell disease is the first illness to be beaten by CRISPR, but the new treatment comes with an expected price tag of $2 to $3 million. CRISPR Therapeutics, Editas Medicine, Precision BioSciences ...
Researchers are further improving CRISPR's versatility to engineer new grasses and yeasts for biochemical production. CRISPR/Cas systems have undergone tremendous advancement in the past decade. These ...
For some diseases, gene therapies offer the potential for lifelong disease amelioration and even cure. And these immensely important novel biotechnologies may be on the cusp of a boom. That is in part ...
The genetic medicines field is working toward therapies capable of doing their editing work inside the body by reaching many different types of tissue and cell types. Regeneron Pharmaceuticals and ...
WEST LAFAYETTE, Ind. — More than a decade ago, scientists harnessed a bacterial molecular machine that identifies and cuts specific sections of DNA, revolutionizing the ability to edit genes and ...
CRISPR Therapeutics now has an approved product in its portfolio in Casgevy. The treatment has the potential to be a game changer for the company's business. Even with more treatments in its portfolio ...
December has been a big month for CRISPR Therapeutics (CRSP 0.98%). On Dec. 8, the Food and Drug Administration (FDA) granted approval for CRISPR's gene-editing therapy, Casgevy, as a treatment for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback